Lynch, T J <br/><br/>
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.  [electronic resource] 

 -  Seminars in oncology  Jun 2001 
 - 5-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0093-7754 
<br/><br/><label>Standard No.: </label>10.1053/sonc.2001.24601  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Alkylating--therapeutic use<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Trials, Phase III as Topic<br/>Docetaxel<br/>Humans<br/>Ifosfamide--therapeutic use<br/>Lung Neoplasms--drug therapy<br/>Paclitaxel--analogs & derivatives<br/>Quality of Life<br/>Radiation-Sensitizing Agents--therapeutic use<br/>Randomized Controlled Trials as Topic<br/>Survival Rate<br/>Taxoids<br/>Vinblastine--analogs & derivatives<br/>Vinorelbine